These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19209419)

  • 21. Editorial comment.
    Chen DY
    J Urol; 2009 Nov; 182(5):2120-1; discussion 2122. PubMed ID: 19758612
    [No Abstract]   [Full Text] [Related]  

  • 22. Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
    Patel A
    Eur Urol; 2008 May; 53(5):982-3. PubMed ID: 17997023
    [No Abstract]   [Full Text] [Related]  

  • 23. Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values.
    Chun FK; Briganti A
    Eur Urol; 2008 Sep; 54(3):702. PubMed ID: 18403097
    [No Abstract]   [Full Text] [Related]  

  • 24. Re: Editorial: the central role of prostate specific antigen in diagnosis and progression of prostate cancer.
    Lawrence G
    J Urol; 1996 Aug; 156(2 Pt 1):484. PubMed ID: 8683715
    [No Abstract]   [Full Text] [Related]  

  • 25. Editorial comment.
    Garzotto M
    J Urol; 2010 Aug; 184(2):500. PubMed ID: 20620407
    [No Abstract]   [Full Text] [Related]  

  • 26. Editorial comment.
    Murtola T
    J Urol; 2010 Aug; 184(2):500. PubMed ID: 20620406
    [No Abstract]   [Full Text] [Related]  

  • 27. Editorial comment.
    Prasad SM; Keane T; Bennett CL
    Urology; 2012 Sep; 80(3):563. PubMed ID: 22789296
    [No Abstract]   [Full Text] [Related]  

  • 28. The utility of PSA doubling time to monitor prostate cancer recurrence.
    Wieder JA; Belldegrun AS
    Mayo Clin Proc; 2001 Jun; 76(6):571-2. PubMed ID: 11393493
    [No Abstract]   [Full Text] [Related]  

  • 29. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
    Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
    J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Editorial comment from Dr Urakami to impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy.
    Urakami S
    Int J Urol; 2014 Oct; 21(10):990-1. PubMed ID: 24909066
    [No Abstract]   [Full Text] [Related]  

  • 31. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.
    Eggener S
    Eur Urol; 2009 Mar; 55(3):616. PubMed ID: 18639973
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial Comment to Prostate-specific antigen-based prostate cancer screening: Past and future.
    Sakamoto S
    Int J Urol; 2015 Jun; 22(6):532-3. PubMed ID: 25854711
    [No Abstract]   [Full Text] [Related]  

  • 33. [Dynamics of prostate-specific antigen concentration--growth kinetics of prostate cancer?].
    Bogomolov ; Zharinov GM; Shkol'nik MI
    Vopr Onkol; 2014; 60(4):437-48. PubMed ID: 25552062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial comment from Dr Simonato and Dr Romagnoli to impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy.
    Simonato A; Romagnoli A
    Int J Urol; 2014 Oct; 21(10):991. PubMed ID: 24931339
    [No Abstract]   [Full Text] [Related]  

  • 35. [PSA doubling times of prostate carcinoma managed with watchful observation alone].
    Dunst J
    Strahlenther Onkol; 2001 Dec; 177(12):684-5. PubMed ID: 11789411
    [No Abstract]   [Full Text] [Related]  

  • 36. Editorial Comment to Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer.
    Yashi M
    Int J Urol; 2015 Jun; 22(6):561-2. PubMed ID: 25799888
    [No Abstract]   [Full Text] [Related]  

  • 37. Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time.
    Hanks GE; D'Amico A; Epstein BE; Schultheiss TE
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(1):125-7. PubMed ID: 7690014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
    Moul JW; Tang P; Sun L
    Eur Urol; 2010 Mar; 57(3):452. PubMed ID: 19303696
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines.
    Carter HB; Pearson JD
    Urology; 1999 Nov; 54(5):780-6. PubMed ID: 10565733
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial Comment from Dr Satoh to interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer.
    Satoh T
    Int J Urol; 2013 Feb; 20(2):149. PubMed ID: 22924812
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.